Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Hutter

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Leukemia|June 8, 2026
Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosisJana Wobst, Marietta Truger, Natalie Wossidlo, et al.
Blood Advances|November 4, 2020
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDSAnna Stengel, Rabia Shahswar, Torsten Haferlach, et al.
Cancer Gene Therapy|February 11, 2022
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesisHeiko Müller, Wencke Walter, Stephan Hutter, et al.
Leukemia|September 28, 2024
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phaseWencke Walter, Niroshan Nadarajah, Stephan Hutter, et al.
Leukemia|October 21, 2022
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phaseSandra Huber, Torsten Haferlach, Manja Meggendorfer, et al.
Haematologica|July 6, 2019
"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?Constance Baer, Wencke Walter, Stephan Hutter, et al.
Blood Cancer Journal|May 19, 2025
Two ways to complex karyotype in MDS-the role of del(5q) and TP53Sandra Huber, Stephan Hutter, Constance Baer, et al.
British Journal of Haematology|April 14, 2026
Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutationsSandra Huber, Christoph Kornauth, Stephan Hutter, et al.
Leukemia|June 20, 2022
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogeneticsIrene Fuhrmann, Miriam Lenk, Torsten Haferlach, et al.
Leukemia|February 22, 2023
MDS subclassification-do we still have to count blasts?Sandra Huber, Torsten Haferlach, Heiko Müller, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Leukemia|June 8, 2026
Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosisJana Wobst, Marietta Truger, Natalie Wossidlo, et al.
Blood Advances|November 4, 2020
Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDSAnna Stengel, Rabia Shahswar, Torsten Haferlach, et al.
Cancer Gene Therapy|February 11, 2022
Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesisHeiko Müller, Wencke Walter, Stephan Hutter, et al.
Leukemia|September 28, 2024
Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phaseWencke Walter, Niroshan Nadarajah, Stephan Hutter, et al.
Leukemia|October 21, 2022
SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phaseSandra Huber, Torsten Haferlach, Manja Meggendorfer, et al.
Haematologica|July 6, 2019
"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?Constance Baer, Wencke Walter, Stephan Hutter, et al.
Blood Cancer Journal|May 19, 2025
Two ways to complex karyotype in MDS-the role of del(5q) and TP53Sandra Huber, Stephan Hutter, Constance Baer, et al.
British Journal of Haematology|April 14, 2026
Genetic characterization of AML defined by differentiation shows a high frequency of DDX41 mutationsSandra Huber, Christoph Kornauth, Stephan Hutter, et al.
Leukemia|June 20, 2022
AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogeneticsIrene Fuhrmann, Miriam Lenk, Torsten Haferlach, et al.
Leukemia|February 22, 2023
MDS subclassification-do we still have to count blasts?Sandra Huber, Torsten Haferlach, Heiko Müller, et al.
Pageof 8